[go: up one dir, main page]

UA117116C2 - Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм - Google Patents

Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм

Info

Publication number
UA117116C2
UA117116C2 UAA201505480A UAA201505480A UA117116C2 UA 117116 C2 UA117116 C2 UA 117116C2 UA A201505480 A UAA201505480 A UA A201505480A UA A201505480 A UAA201505480 A UA A201505480A UA 117116 C2 UA117116 C2 UA 117116C2
Authority
UA
Ukraine
Prior art keywords
treatment
telomerase inhibitor
myeloproliferative neoplasms
methods
myeloproliferative disorders
Prior art date
Application number
UAA201505480A
Other languages
English (en)
Inventor
Монік Дж. Стюарт
Стівен Келсі
Original Assignee
Джерон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Джерон Корпорейшн filed Critical Джерон Корпорейшн
Publication of UA117116C2 publication Critical patent/UA117116C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Винахід стосується способу зменшення проліферації клітин-попередників і полегшення симптому, що є наслідком мієлофіброзу, у індивідуума, шляхом введення інгібітора теломерази, який є олігонуклеотидом з такими характеристиками: а) довжина дорівнює 8-20 основам; та b) комплементарний РНК-компоненту теломерази.
UAA201505480A 2012-12-07 2013-11-15 Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм UA117116C2 (uk)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05
PCT/US2013/070437 WO2014088785A1 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
UA117116C2 true UA117116C2 (uk) 2018-06-25

Family

ID=50883867

Family Applications (3)

Application Number Title Priority Date Filing Date
UAA201800703A UA126015C2 (uk) 2012-12-07 2013-11-15 Використання інгібіторів теломерази для лікування мієлопроліферативних порушень і мієлопроліферативних неоплазм
UAA201505480A UA117116C2 (uk) 2012-12-07 2013-11-15 Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм
UAA202100419A UA128370C2 (uk) 2012-12-07 2013-11-15 Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201800703A UA126015C2 (uk) 2012-12-07 2013-11-15 Використання інгібіторів теломерази для лікування мієлопроліферативних порушень і мієлопроліферативних неоплазм

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA202100419A UA128370C2 (uk) 2012-12-07 2013-11-15 Використання інгібітора теломерази для лікування мієлопроліферативних неоплазм

Country Status (37)

Country Link
EP (3) EP3646876B1 (uk)
JP (6) JP6433911B2 (uk)
KR (4) KR20250114449A (uk)
CN (2) CN111617252A (uk)
AP (1) AP2015008504A0 (uk)
AU (4) AU2013356533B2 (uk)
BR (1) BR112015013260A2 (uk)
CA (2) CA3188494A1 (uk)
CL (2) CL2015001530A1 (uk)
CY (2) CY1122169T1 (uk)
DK (3) DK2928477T3 (uk)
EA (1) EA032973B1 (uk)
ES (3) ES2982897T3 (uk)
FI (2) FI3646876T3 (uk)
FR (1) FR25C1016I1 (uk)
HK (1) HK1210940A1 (uk)
HR (3) HRP20191784T1 (uk)
HU (4) HUE049858T2 (uk)
IL (3) IL317233A (uk)
LT (4) LT2928477T (uk)
MA (2) MA45504B1 (uk)
ME (1) ME03538B (uk)
MX (3) MX372753B (uk)
MY (2) MY200076A (uk)
NL (1) NL301326I2 (uk)
NZ (1) NZ708920A (uk)
PH (2) PH12019501008A1 (uk)
PL (3) PL3646876T3 (uk)
PT (3) PT3456333T (uk)
RS (2) RS59363B1 (uk)
SG (3) SG11201504383TA (uk)
SI (3) SI3646876T1 (uk)
SM (2) SMT202000328T1 (uk)
TN (1) TN2015000249A1 (uk)
UA (3) UA126015C2 (uk)
WO (1) WO2014088785A1 (uk)
ZA (3) ZA201504124B (uk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2868452T3 (es) 2004-07-02 2021-10-21 Geron Corp Síntesis de monómeros nucleosídicos 5'fosforamidita 3’ aminoprotegidos
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
CN114010611B (zh) 2013-08-07 2023-11-28 因赛特控股公司 Jak1抑制剂的持续释放剂型
HRP20190538T1 (hr) * 2013-11-06 2019-05-17 Mayo Foundation For Medical Education And Research Postupci i materijali za liječenje hematoloških malignosti
MA42157A (fr) 2015-04-23 2018-02-28 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
UA127701C2 (uk) * 2017-07-28 2023-12-06 Джерон Корпорейшн Спосіб лікування мієлодиспластичного синдрому (варіанти)
IL319432A (en) 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
KR20210043499A (ko) * 2018-05-25 2021-04-21 카토스 테라퓨틱스, 인크. 골수증식성 신생물 치료 방법
CN120093922A (zh) * 2018-07-31 2025-06-06 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
JP7650798B2 (ja) 2018-11-29 2025-03-25 ジェロン・コーポレーション 骨髄異形成症候群を治療する方法
KR20220130669A (ko) * 2019-11-04 2022-09-27 제론 코포레이션 골수증식성 신생물의 치료를 위한 야누스 키나제 저해제 및 텔로머라제 저해제의 용도
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
MX2023000760A (es) * 2020-07-17 2023-02-13 Geron Corp Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso.
EP4281560A4 (en) * 2021-01-22 2025-04-16 The Regents of the University of California METHODS FOR THE TREATMENT AND Palliation of Cancer
WO2024259369A1 (en) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
EP0951568A1 (en) 1996-12-20 1999-10-27 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2515000A1 (en) * 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
SI3342425T1 (sl) 2003-09-09 2020-04-30 Geron Corporation Modificirani oligonukleotidi za inhibicijo telomeraze
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
ES2868452T3 (es) 2004-07-02 2021-10-21 Geron Corp Síntesis de monómeros nucleosídicos 5'fosforamidita 3’ aminoprotegidos
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
ATE553198T1 (de) 2005-04-15 2012-04-15 Geron Corp Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
PT2101789E (pt) * 2006-10-30 2015-03-24 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
FIC20250019I1 (fi) 2025-05-07
HUE049858T2 (hu) 2020-11-30
JP2022050537A (ja) 2022-03-30
NZ748134A (en) 2020-10-30
DK3456333T3 (da) 2020-05-18
JP2020041001A (ja) 2020-03-19
CL2015001530A1 (es) 2016-03-28
BR112015013260A2 (pt) 2018-02-06
CY1123206T1 (el) 2021-10-29
PT3456333T (pt) 2020-06-01
FI3646876T3 (fi) 2024-05-14
EA032973B1 (ru) 2019-08-30
HK1210940A1 (zh) 2016-05-13
AU2013356533A1 (en) 2014-06-12
AU2024203138A1 (en) 2024-07-25
CN104936602A (zh) 2015-09-23
PH12015501282B1 (en) 2015-08-24
SMT201900567T1 (it) 2019-11-13
EP3646876A1 (en) 2020-05-06
PL2928477T3 (pl) 2020-03-31
CN111617252A (zh) 2020-09-04
KR102662590B1 (ko) 2024-05-03
AU2020267142B2 (en) 2024-05-16
EP3456333B1 (en) 2020-04-01
ZA202108991B (en) 2023-05-31
JP2018035196A (ja) 2018-03-08
JP2025109842A (ja) 2025-07-25
AP2015008504A0 (en) 2015-06-30
LT2928477T (lt) 2019-10-10
PT3646876T (pt) 2024-05-15
LT3646876T (lt) 2024-05-10
EP2928477B1 (en) 2019-07-24
ZA202212327B (en) 2025-03-26
ZA201504124B (en) 2017-05-31
PL3456333T3 (pl) 2020-09-21
KR20230028590A (ko) 2023-02-28
JP6998191B2 (ja) 2022-02-04
ES2744790T3 (es) 2020-02-26
UA126015C2 (uk) 2022-08-03
KR20210107906A (ko) 2021-09-01
AU2020267142C1 (en) 2024-08-08
EP3646876B1 (en) 2024-02-14
ES2982897T3 (es) 2024-10-18
HRP20240624T1 (hr) 2024-08-02
SI2928477T1 (sl) 2019-11-29
CN104936602B (zh) 2020-07-17
RS60401B1 (sr) 2020-07-31
MY200076A (en) 2023-12-06
HUE066402T2 (hu) 2024-07-28
MA45504B1 (fr) 2021-10-29
WO2014088785A8 (en) 2015-07-16
NZ708920A (en) 2020-08-28
LT3456333T (lt) 2020-06-25
PH12019501008A1 (en) 2022-11-14
SI3456333T1 (sl) 2020-10-30
MA45504A1 (fr) 2020-05-29
SI3646876T1 (sl) 2024-07-31
PT2928477T (pt) 2019-10-25
ES2789176T3 (es) 2020-10-26
CA2892907C (en) 2023-03-21
NL301326I2 (nl) 2025-07-31
LTPA2025517I1 (uk) 2025-05-26
WO2014088785A1 (en) 2014-06-12
EP2928477A4 (en) 2016-09-21
IL280144A (en) 2021-03-01
PL3646876T3 (pl) 2024-07-22
TN2015000249A1 (en) 2016-10-03
JP6433911B2 (ja) 2018-12-05
EP3456333B8 (en) 2020-05-13
HUS2500019I1 (hu) 2025-05-28
IL280144B2 (en) 2025-05-01
JP2022179684A (ja) 2022-12-02
MA38193B1 (fr) 2018-12-31
EA201590878A1 (ru) 2016-04-29
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
FR25C1016I1 (fr) 2025-06-20
KR20250114449A (ko) 2025-07-29
CL2017002156A1 (es) 2018-05-04
KR20150091130A (ko) 2015-08-07
MY180634A (en) 2020-12-03
ME03538B (me) 2020-07-20
DK3646876T3 (da) 2024-05-06
UA128370C2 (uk) 2024-06-26
MX2015007169A (es) 2016-03-31
SG11201504383TA (en) 2015-07-30
HRP20191784T1 (hr) 2019-12-27
AU2013356533B2 (en) 2018-09-27
CY1122169T1 (el) 2020-11-25
IL317233A (en) 2025-01-01
KR102294819B1 (ko) 2021-09-01
DK2928477T3 (da) 2019-10-07
MA38193A1 (fr) 2017-12-29
EP2928477A1 (en) 2015-10-14
IL239266B (en) 2019-11-28
CA3188494A1 (en) 2014-06-12
RS59363B1 (sr) 2019-11-29
IL239266A0 (en) 2015-07-30
PH12015501282A1 (en) 2015-08-24
JP2016504307A (ja) 2016-02-12
MX2022015437A (es) 2023-01-11
MX372753B (es) 2020-06-26
IL280144B1 (en) 2025-01-01
SMT202000328T1 (it) 2020-07-08
AU2018282364A1 (en) 2019-05-23
CA2892907A1 (en) 2014-06-12
HK1212226A1 (en) 2016-06-10
AU2020267142A1 (en) 2020-12-03
MX2020003276A (es) 2020-07-20
EP3456333A1 (en) 2019-03-20
SG10202103341SA (en) 2021-05-28
SG10201802926XA (en) 2018-05-30
JP7288098B2 (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
ZA202212327B (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201590301A1 (ru) Композиции и способы уменьшения содержания алкоголя в крови
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
GB2510524A (en) Pulmonary hypertension
MX352997B (es) Derivados de espirotienopiran-piperidina como antagonistas del receptor orl-1 para su uso en el tratamiento de dependencia y abuso de alcohol.
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
AU2013208087A8 (en) Tryptoline derivatives having kinase inhibitory activity and uses thereof
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201990799A1 (ru) Использование ингибиторов теломеразы для лечения миелопролиферативных нарушений и миелопролиферативных неоплазм
MA54889A1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
UA112059C2 (uk) Комбінована терапія із кріохірургією і іміквімодом для лікування актинічного кератозу (варіанти)
EA201792475A1 (ru) Клетки-предшественники мезодермальной линии
EA202090141A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
TR201907505T4 (tr) Anti-DR5 ailesi antikorları, bispesifik veya çok değerlikli anti-DR5 ailesi antikorları ve bunların kullanım yöntemleri.